OasisLMS

This program provides a comprehensive update on genetic kidney diseases, including advances in diagnostics, therapeutic approaches, and the clinical integration of genetic testing. Through expert presentations, interactive discussions, and workshops, participants gain practical skills in genetic test interpretation, patient communication, and ethical considerations for integrating nephrogenetics into clinical care. Case-based learning and real-world applications provide actionable insights to enhance patient care and multidisciplinary collaboration in nephrogenetics.

Learning Objectives
Upon completion of the program, the participant will be able to:

• Discuss the latest advancements in genetic kidney disease research
• Differentiate among various genetic testing methodologies with an understanding of genetic test results, including variant classification, variants of uncertain significance, and clinical implications
• Apply ethical considerations when ordering genetic testing and returning results
• Describe diagnostic and management strategies for rare kidney diseases using online resources and databases
• Discuss interdisciplinary collaboration with genetic counselors, nephrology professionals, and researchers to optimize patient outcomes

Target Audience

• Physicians
• Researchers
• Medical and Other Trainees
• Nurses and Nurse Practitioners
• Pharmacists
• Physician Assistants
• Other Healthcare Professionals

Commercial Support
There is no commercial support for this Kidney Week Early Program.

Privacy Policy/Confidentiality
http://www.asn-online.org/terms/privacy.aspx    
    
ASN Medical Disclaimer     
http://www.asn-online.org/terms/medical-disclaimer.aspx

Please note that only learners who participated in this Early Program in-person in Houston can claim credits.

Accreditation Statement

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

AMA Credit Designation Statement – Physicians:
The American Society of Nephrology designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCPA Credit Designation Statement – Physician Assistants:
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society.
Physician Assistants may receive a Certificate of Participation that states this activity has been approved for up to 6.75 AMA PRA Category 1 Credits™.

CME/CPE Deadline Date: December 17, 2025 at 11:59 PM ET
Estimated Time for Completion: 6.75 hours

Method of Participation

1. Participate in the Early Program (verification required).
2. In the activity, click the Questionnaire tab, and complete the Demographics Questionnaire.
3. Complete the General Evaluation.
4. Select the Claim Credit tab. Use the Credit Selection dropdown to select your applicable credit type. If none apply, select None of the Above - Print Participation Certificate.
   1. If a CE credit type is selected:
      1. The number of credits defaults to the maximum amount. Adjust based on your actual participation. 
      2. Select the Claim button.
      3. Select the View Certificate button. It may take up to 15 minutes for your certificate to show.
   2. If None of the Above - Print Participation Certificate is selected:
      1. Select I understand the above - continue to participation certificate.
      2. Select Get Certificate.

Co-Chair(s)

• Arlene B. Chapman, MD
• Emilie Cornec-Le Gall, MD, PhD

A full faculty listing is available here. 

ASN Disclosure Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ASN requires all individuals in a position to control content for Kidney Week Early Programs to disclose all financial relationships with ineligible companies.

All disclosed financial relationships were reviewed by ASN. Any relevant financial relationships with ineligible companies were identified and mitigated prior to the activity.

View the ASN Disclosure Policy here.

• Broadband cable, DSL, or high-speed internet connection
• Please use the latest version of Google Chrome for the best viewing experience. Mozilla and Safari can also be used; however, Microsoft Edge is not recommended. Please check the ASN auto-detect settings page.
• 533 MHz or faster processor
• 512 MB RAM or higher
• Adobe Reader (free download)
• Computer which can play MP3 files
• Apple iPad/iPhone running HTML5
• Android devices